What is next-generation sequencing (NGS) and should I get it for my cancer

May 19, 2026Navis AI

Ask Navis about your situation

This answer is general. Get one about your specific case — no signup, answered right here.

For informational purposes only

This answer was generated by AI grounded in NCCN guidelines and published medical literature. It is not medical advice. Always consult your oncologist or care team before making treatment decisions.

Understanding Next-Generation Sequencing (NGS) for Cancer

What Is NGS?

Next-generation sequencing is a laboratory test that analyzes your cancer's DNA to identify specific genetic mutations and alterations. Think of it like reading the "instruction manual" of your tumor to find what makes it tick.

How it works:

  • A sample of your cancer tissue (from biopsy or surgery) is sent to a lab
  • Scientists extract the DNA from cancer cells
  • Advanced machines read millions of DNA sequences simultaneously
  • Computer analysis identifies mutations, gene amplifications, and other changes
  • Results show which genes are altered in YOUR specific cancer

Why this matters: Different cancers have different genetic "fingerprints." NGS helps identify which mutations are driving your cancer, which can directly influence treatment options.

Common Findings from NGS

NGS might reveal:

  • Actionable mutations (like EGFR, BRAF, KRAS, ALK) that have targeted drugs available
  • Microsatellite instability (MSI) or tumor mutational burden (TMB) - which can predict immunotherapy response
  • Mismatch repair deficiency - relevant for certain treatment approaches
  • Gene amplifications (like HER2) - important for targeted therapy selection

Should You Get NGS?

According to NCCN (National Comprehensive Cancer Network) Guidelines and ASCO (American Society of Clinical Oncology) recommendations, NGS testing is increasingly standard for:

Likely recommended for you if:

  • You have advanced/metastatic cancer (spread beyond original site)
  • You have certain cancer types (lung, colorectal, breast, ovarian, pancreatic)
  • Your initial treatment isn't working as expected
  • You're considering clinical trials
  • Your cancer type has known targetable mutations

Depends on your situation:

  • Early-stage cancers (may not change treatment decisions)
  • Certain tumor types with limited actionable mutations
  • Your insurance coverage and access to testing

Key Questions to Ask Your Oncologist

  1. "Does my cancer type and stage typically benefit from NGS testing?"
  2. "Are there specific mutations in my cancer type that would change my treatment options?"
  3. "Will NGS results affect my treatment plan, or is it mainly for future reference?"
  4. "What's the timeline for results, and how will we discuss them?"
  5. "Does my insurance cover this test, or are there costs I should know about?"

Important Context

NGS can be powerful, but it's not a magic answer. Finding a mutation only matters if:

  • There's a targeted drug available for it
  • That drug is appropriate for your specific situation
  • Your doctor believes it will help your treatment

Your oncologist will integrate NGS results with your complete clinical picture—your cancer stage, overall health, previous treatments, and other factors—to determine the best approach.

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.

Ask Navis about your case

That answer is general. Ask about your specific situation — no signup, answered right here.

Facing this with someone you love?

Keep the whole picture in one private place: records, a plain-language summary of where things stand, questions, and the people helping. Navis keeps it up to date so no one has to re-explain the story. Free, and only the people you invite can ever see it.

Start a care circle →

Related Questions

Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...

```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv

Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...

```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv

Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...

```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv

Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...

```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv

Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...

```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv

We are in the UK royal marsden. It is kind of hopeless or how to say? Is there any immunetherapy worth to pursue or...

TL;DR: Diffuse midline gliomas DMGs with H3K27M are very challenging, but immunotherapy and targeted approaches are actively being researched—the Roya

It is my daughter she completed 6 weeks of radio and tmz now she is on 3rd cycle of tmz 200mg. We are doing low meth...

TL;DR: Your daughter's treatment plan radiation + TMZ chemotherapy is standard for diffuse midline glioma, and her biomarkers MGMT methylated, EGFR A2

It is h3k27 altered dmg h3k27m negative, egfr a289v myc tp53 mgmt methylated

Your tumor has specific genetic changes H3K27, EGFR, MYC, TP53, MGMT that your doctors will use to guide treatment decisions—these findings help deter